MGMT and glioblastoma: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is shown to have survival benefit for glioblastoma patients undergoing maximal safe resection, radiotherapy and concomitant temozolomide (TMZ) followed by 6 cycles of adjuvant TMZ, acting as prognostic marker [8, 12].